- 专利标题: 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
-
申请号: US16069585申请日: 2017-01-09
-
公开(公告)号: US10590128B2公开(公告)日: 2020-03-17
- 发明人: Thomas Allen Chappie , Jaclyn Louise Henderson , Joseph Michael Young , Travis T. Wager , Bethany Lyn Kormos , Nandini Chaturbhai Patel , Simone Sciabola , Jamison Bryce Tuttle , Patrick Robert Verhoest , Joseph Walter Tucker
- 申请人: Pfizer Inc.
- 申请人地址: US NY New York
- 专利权人: Pfizer, Inc.
- 当前专利权人: Pfizer, Inc.
- 当前专利权人地址: US NY New York
- 代理机构: Haley Guiliano LLP
- 代理商 James F. Haley, Jr.; Brittany J. Barrett
- 国际申请: PCT/IB2017/050094 WO 20170109
- 国际公布: WO2017/122116 WO 20170720
- 主分类号: C07D471/04
- IPC分类号: C07D471/04 ; A61K31/55 ; A61P25/16 ; A61P25/18 ; A61P25/24 ; A61P25/22
摘要:
The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.
公开/授权文献
信息查询